glp-1 ra drugs Mapping the effectiveness and risks of receptor agonists Exploring GLP-1 Receptor Agonists (GLP-1

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease (NAFLD), has seen its global prevalence surge from 25% between 1990 and 2006 to 38% between 2016 and 2019

GLP-1 reduces neuroinflammation and also affects centers in the brain that are responsible for impulse control and reward signaling there are many studies showing that we indeed have GLP-1 receptors in our brain

Sang, P

doi: 10.1001/jama.2019.22360 57 JankovicJTanEK

Patients with Cardiovascular Risk Factors: Research suggests that GLP1 receptor agonists may provide cardiovascular benefits, including reduced risk of heart attack and stroke in patients with type 2 diabetes